Abstract
Cisplatin and its analogs are potent chemotherapeutic agents in the treatment of ovarian cancer, testicular cancer, and other malignancies. Studies by this group have shown that the level of platinum-DNA adduct formed in leukocyte DNA is directly related to disease response in ovarian cancer (Reed et al, 1987) and testicular cancer (Reed et al, 1988a), and that the level of adduct attained is influenced by the persistence of the adduct in leukocyte precursors in some patients for no less than 28 days (Reed et al, 1986). Because this persistence has been observed in some patients but not in others (Reed et al, 1986), we have been interested in the study of those factors that may influence persistence, and whether these factors are directly related to clinical parameters and/or subcellular parameters of cisplatin drug resistance. We have assessed the relative contribution of clinical parameters to disease response in a cohort of patients with ovarian cancer, and we compare those data to platinum-DNA adduct measurements in leukocyte DNA from these same individuals.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bohr, V.A., Chu, E.H.Y., van Duin, M., Hanawalt, P.C., and Okumoto, D. S., 1988, Human repair gene restores normal pattern of preferential DNA repair in repair defective CHO cells, Nucleic Acids Res, 16: 7397.
Conover, W.J., 1980, “Practical Non-Parametric Statistics,” 2nd ed. Johns Wiley and Sons, New York.
Davis, L.G., Dibner, M.D., and Battey, J.F., 1986, “Basic Methods in Molecular Biology,” Elsevier, New York.
Fairchild, C.R., Ivy, S.P., Rushmore, T., Lee, G., Koop, Goldsmith, M.E., Myers, C.E., Farber, E., and Cowan, K.H., 1987, Carcinogen induced mdr expression is associated with xenobiotic resistance in rat preneo- plastic liver nodules and hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 84: 7701.
Flamm, W.H., Birnsteil, M.L., and Walter, P.M.B., 1969, in: “Subcellular Components: Preparation and Fractionation,” G. Birnie and S.M. Fox, eds, Butterworth and Co., Ltd., London.
Hoeijmakers, J.H.J., 1987, Characterization of genes and proteins involved in excision repair of human cells, J Cell Sci (Suppl 6), 111.
Kraker, A.J., and Moore, C.W., 1988, Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line, Cancer Letters, 38: 307.
Lu, Y., Han, J., and Scanlon, K.J., 1988, Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid, J Biol Chem, 263: 4891.
Ozols, R.F., Ostchega, Y., Myers C.E., and Young, R.C., 1985, High dose cisplatin in hypertonic saline in refractory ovarian cancer patients, J Clin Oncol, 3: 1246.
Ozols, R.F., Ostchega, Y., Curt, G.A., and Young, R.C., 1987, High dose carboplatin in refractory ovarian cancer patients, J Clin Oncol, 5: 197.
Reed, E., 1989, Cisplatin. in “Cancer Chemotherapy and Biological Response Modifiers Annual - Volume 11,” H.M. Pinedo, B.A Chabner, and D.L. Longo, eds, Elsevier Science Publishers B.V., Amsterdam, in press.
Reed, E., Yuspa, S.H., Zwelling, L.A., Ozols, R.F., and Poirier, M.C., 1986, Quantitation of cisplatin-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy, J. Clin. Invest., 77: 545.
Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C., 1987, Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy, Proc. Natl. Acad. Sci. USA, 84: 5024.
Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C., 1988a, The measurement of cisplatin-DNA adduct levels in testicular cancer patients, Carcinogenesis, 9: 1909.
Reed, E., Sauerhoff, S., and Poirier, M.C., 1988b, Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure - A novel use of graphite furnace spectrometry, Atomic Spectroscopy, 9: 93.
Reed, E., Poirier, M.C., Young, R.C., Ozols, R.F., 1988c, High dose cisplatin in hypertonic salines Toxicity versus therapeutic benefit, in: “Organ Directed Toxicities of Anti-Cancer Drugs,” H.P. Hacker, J.S. Lazo, and T.R. Tritton, eds., Martinus Nijhoff Publishers, Boston.
Scanlon, K.J., and Kashani-Sabet, M., 1988, Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells, Proc Natl Acad Sci USA, 85: 650.
Van Duin, M., de Wit, J., Odijk, H., Westerveld, A., Yasui, A., Koken, M.H.M., Hoeijmakers, J.H.J., and Bootsma, D., 1986, Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO, Cell, 44: 913.
Westerveld, A., Hoeijmakers, J.H.J., van Duin, M., de Wit, J., Odijk, H., Pastink, A., Wood, R.D., and Bootsma, D., 1984, Molecular cloning of a human DNA repair gene, Nature, 310: 425.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Press, New York
About this chapter
Cite this chapter
Parker, R.J., Poirier, M.C., Bostick-Bruton, F., Vionnet, J., Bohr, V.A., Reed, E. (1990). Peripheral Blood Leukocytes as a Surrogate Marker for Cisplatin Drug Resistance: Studies of Adduct Levels and the Repair Gene ERCC1. In: Sutherland, B.M., Woodhead, A.D. (eds) DNA Damage and Repair in Human Tissues. Basic Life Sciences, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0637-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0637-5_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-7903-7
Online ISBN: 978-1-4613-0637-5
eBook Packages: Springer Book Archive